Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, timely and earlier diagnosis is critical.EchoGo®...
Boston Children's Hospital, Memorial Sloan Kettering, MyEyeDr., Northwestern Medicine, Novant Health, OhioHealth, VCA Animal Hospitals, and more offer early job...
BINYAMINA, Israel and CARY, N.C., July 9, 2025 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine...
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent...
Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery System; Company is Currently Conducting...
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of...
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year...
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued...
NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE)...
Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidatesIambic to receive up to $25...
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with...
Proceeds to support key development milestones, including CMC advancement, initiation of a Phase I clinical trial in the first half...
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term...
ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without ToleranceSOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo...
Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS in Phase 1/2a studyNo treatment limited toxicities...
Pairing of custom-built klystrons and fast-pulse modulators enable production of up to 12 radioisotopes in a single run Power and...
WALTHAM, Mass., July 8, 2025 /PRNewswire/ -- Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early...
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- As artificial intelligence...